

FOR IMMEDIATE RELEASE

**Seoul National University Hospital Signs Five Year Agreement with OmniComm Systems[®] TrialOne[®]
for Clinical Research Automation**

OmniComm Systems, Inc. Expands Market Presence in Asia

Fort Lauderdale, FL, April 3, 2014 - OmniComm Systems, Inc. (OTC: OMCM), a global leading provider of clinical data management solutions for clinical trials, signed a five year agreement with Seoul National University Hospital (SNUH) Clinical Trials Center, a leading academic medical center in the Republic of Korea, to use OmniComm Systems' market leading TrialOne technology for automation within its Phase I clinical pharmacology studies.

SNUH conducted an exhaustive evaluation with a specific emphasis on subject recruitment, study data capture, sample tracking, reporting, data management and integration with laboratory and medical monitoring equipment and found TrialOne superior in all categories when compared to other commercially available technologies. The depth in functionality and foreign language capabilities were a significant factor in the decision.

"TrialOne will greatly improve our research environment," states Prof. Yung-Jue Bang, M.D., Ph.D., president Biomedical Research Institute SNUH and director SNUH Clinical Trials Center. "Not only will it automate many study activities, but it will also upgrade our clinical trials system by enabling more streamlined work flows. This will lead to a drastic increase in the quality of clinical trials and their related services to our valued clients."

"The fact that our colleagues at one of the most prestigious institutions in Korea have chosen for TrialOne in addition to Promasys demonstrates that the OmniComm software range is increasingly suitable also for academic centers of excellence," adds Adam Cohen, M.D. Ph.D., OmniComm Systems board member, professor of pharmacology and CEO Centre for Human Drug Research (CHDR). "CHDR has a long standing collaboration with SNUH with an exchange program for research fellows. The collaborative research that emanates from this is facilitated greatly by the use of similar software systems."

"This is the first customer for TrialOne in Asia, but certainly not the last," says Wolf Ondracek, senior vice president Academic and Asian Markets, OmniComm Systems. "Seoul National University ranks high in all the international university rankings, and their hospital is one of the leading medical centers in the East-Asia region and a top medical institute in Korea. In 2012, SNUH Clinical Trials Center was selected as a Global Center of Excellence in Early Phase Clinical Trials by the Korean Ministry of Health and Welfare. Their ambition is to become one of the leading early phase clinical trials centers in the world by 2022 and we are proud that our TrialOne solution will be an important tool to achieve that goal."

Supporting Information

[TrialOne](#)

[Promasys](#)

About Seoul National University Hospital

Seoul National University Hospital has been looking after public health over the past 100 years, leading the development of medicine in Korea. It was established in 1885 as Korea's first national hospital under the name of Kwang Hye Won. Later it became the affiliate hospital for Seoul National University's College of Medicine and College of Dentistry before being recognized as a special corporate body under the name of Seoul National University Hospital.

Today the hospital is comprised of the Main Hospital, the Children's Hospital, the Cancer Hospital, the Dental Hospital, and the Clinical Research Institute. Over 1,700 hospital beds, approximately 2,000 inpatients and 8,000 outpatients are treated each day by 533 medical professors and 5,800 staff.

With the arrival of the 21st century, Seoul National University Hospital is striving to develop into a world-class hospital, safeguarding the health of mankind. The hospital's vision for the 21st century is based on patient-oriented care, respect for mankind, the creation of knowledge and public service. For more information, please visit www.snuh.org.

In 2006, Seoul National University Hospital was one of the first academic centers in Asia to become a user of Promasys, the clinical data management system originally developed at the Centre for Human Drug Research, and now OmniComm's data capture and data management solution for academic customers. Seoul National University Hospital will continue using Promasys as a data capture and data management system for their later phase investigator initiated trials.

About OmniComm Systems

OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world's pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive



OmniComm System, Inc
3500 West Commercial Blvd.
Suite 3500
Fort Lauderdale, FL 33309 USA
Phone: +1.954.473.1254
Fax: +1.954.473.1256
www.omnicomm.com

solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Trademarks

OmniComm, TrialMaster, TrialOne, eClinical Suite and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.

Contact Info

Kuno van der Post, Ph.D.
OmniComm Systems, Inc.
+1.954.473.1254
KVanderPost@omnicomm.com